Tags

Type your tag names separated by a space and hit enter

Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam.

Abstract

1. The purpose of this study was to compare the effects and abrupt discontinuation of buspirone 15 or 20 mg tid and lorazepam 3 or 4 mg tid following 8 weeks of treatment. A total of 43 outpatients with generalized anxiety disorder were included in the study and 39 entered the withdrawal phase. 2. Clinical assessments were performed at baseline, 2, 4, 6 and 8 weeks (active phase) and after 9 and 10 weeks (withdrawal phase). These included the Hamilton anxiety scale, the visual analogue scale, the CHESS 84 (a check list for the evaluation of somatic symptoms) and the Lader tranquilizer withdrawal scale (translated in french). 3. Results show similar efficacy for lorazepam and buspirone during the active phase with a higher significant difference for buspirone on the CHESS 84 in relation with neurovegetatives symptoms: lorazepam D0 :16.30 +/- 3.14 D56: 5.10 +/- 0.93 (p < or = 0.01) buspirone D0 :18.82 +/- 3.4 D56: 4.73 +/- 1.18 (p < or = 0.001) No withdrawal phenomena was observed for both drugs using HAM-A lorazepam D63 :12.59 +/- 2.26 D70: 12.0 +/- 1.75 (p = ns) buspirone D63 :10.05 +/- 1.28 D70: 10.32 +/- 1.82 (p = ns) and the same significant difference using Lader scale: lorazepam D63 :4.44 +/- 0.89 D70: 6.96 +/- 1.28 (p < or = 0.05) buspirone D63 :2.95 +/- 0.66 D70: 4.15 +/- 0.92 (p < or = 0.05). 4. This study confirmed that buspirone was as effective as lorazepam at D56 in monitored outpatients with generalized anxiety disorder.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Groupe de Recherche Neurobiologie de l'anxiéte et GIS Médicament, Faculté de Médecine, Nantes France.No affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

8588056

Citation

Bourin, M, and M Malinge. "Controlled Comparison of the Effects and Abrupt Discontinuation of Buspirone and Lorazepam." Progress in Neuro-psychopharmacology & Biological Psychiatry, vol. 19, no. 4, 1995, pp. 567-75.
Bourin M, Malinge M. Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19(4):567-75.
Bourin, M., & Malinge, M. (1995). Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam. Progress in Neuro-psychopharmacology & Biological Psychiatry, 19(4), 567-75.
Bourin M, Malinge M. Controlled Comparison of the Effects and Abrupt Discontinuation of Buspirone and Lorazepam. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19(4):567-75. PubMed PMID: 8588056.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam. AU - Bourin,M, AU - Malinge,M, PY - 1995/7/1/pubmed PY - 1995/7/1/medline PY - 1995/7/1/entrez SP - 567 EP - 75 JF - Progress in neuro-psychopharmacology & biological psychiatry JO - Prog. Neuropsychopharmacol. Biol. Psychiatry VL - 19 IS - 4 N2 - 1. The purpose of this study was to compare the effects and abrupt discontinuation of buspirone 15 or 20 mg tid and lorazepam 3 or 4 mg tid following 8 weeks of treatment. A total of 43 outpatients with generalized anxiety disorder were included in the study and 39 entered the withdrawal phase. 2. Clinical assessments were performed at baseline, 2, 4, 6 and 8 weeks (active phase) and after 9 and 10 weeks (withdrawal phase). These included the Hamilton anxiety scale, the visual analogue scale, the CHESS 84 (a check list for the evaluation of somatic symptoms) and the Lader tranquilizer withdrawal scale (translated in french). 3. Results show similar efficacy for lorazepam and buspirone during the active phase with a higher significant difference for buspirone on the CHESS 84 in relation with neurovegetatives symptoms: lorazepam D0 :16.30 +/- 3.14 D56: 5.10 +/- 0.93 (p < or = 0.01) buspirone D0 :18.82 +/- 3.4 D56: 4.73 +/- 1.18 (p < or = 0.001) No withdrawal phenomena was observed for both drugs using HAM-A lorazepam D63 :12.59 +/- 2.26 D70: 12.0 +/- 1.75 (p = ns) buspirone D63 :10.05 +/- 1.28 D70: 10.32 +/- 1.82 (p = ns) and the same significant difference using Lader scale: lorazepam D63 :4.44 +/- 0.89 D70: 6.96 +/- 1.28 (p < or = 0.05) buspirone D63 :2.95 +/- 0.66 D70: 4.15 +/- 0.92 (p < or = 0.05). 4. This study confirmed that buspirone was as effective as lorazepam at D56 in monitored outpatients with generalized anxiety disorder.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0278-5846 UR - https://www.unboundmedicine.com/medline/citation/8588056/Controlled_comparison_of_the_effects_and_abrupt_discontinuation_of_buspirone_and_lorazepam_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0278584695001022 DB - PRIME DP - Unbound Medicine ER -